The presence of early atheroma in antiphospholipid syndrome (APS) underscores the
necessity of new therapies for this disorder. Inflammation plays an essential role in the …

Background The cornerstone of thrombotic antiphospholipid syndrome (APS) patients'
management is to prevent recurrent thrombosis by long-term anticoagulation. Purpose of …

Background Long-term anticoagulation is recommended in antiphospholipid syndrome with
thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K …

There is a scarcity of high-quality randomized controlled trials (RCTs) comparing
antithrombotic regimens for secondary prevention of arterial thrombosis (AT) in …

Objective To perform a systematic literature review (SLR) informing the European
Lmmendations for the management of antiphospholipid syndrome (APS) in adults. Methods …

The current mainstay of treatment of thrombotic APS is long-term anticoagulation with oral
vitamin K antagonists (VKA) such as warfarin. However, the use of warfarin is problematic …

Antibodies against phospholipid (aPL)-binding proteins, in particular, beta 2 glycoprotein I
(β2GPI), are diagnostic/classification and pathogenic antibodies in antiphospholipid …

Antiphospholipid (aPL) antibodies (Abs) are associated with thrombosis and pregnancy loss
in antiphospholipid syndrome (APS), a disorder initially characterised in patients with …

Antiphospholipid antibody syndrome (APS) is an autoimmune acquired thrombophilia
characterized by recurrent thrombosis and pregnancy morbidity in the presence of …

Persistently positive antiphospholipid antibodies in association with thromboses and/or
pregnancy morbidity is the hallmark of the antiphospholipid syndrome. The management of …